Increased Usability and Precision in Vascular Imaging
Researchers at the University of Zurich have developed a new X-ray contrast agent. The contrast agent is easier to use and distributes into all blood vessels more reliably, increasing the precision of vascular imaging. This reduces the number of animals required in research experiments.
Article of uzh.ch
Various diseases in humans and animals – such as tumors, strokes or chronic kidney disease – damage the blood vessels. Capillaries, the smallest blood vessels in the body, are particularly affected. The large surface area of the capillary network enables oxygen to be exchanged between the blood and the surrounding tissue, such as the muscles when we exercise or the brain when we think.
Revealing the vascular structure
For the diagnosis and treatment of cardiovascular and other diseases, it is important to know the three-dimensional structure of blood vessels. This knowledge of the exact anatomy of the capillaries in humans and animals is also crucial for basic research. It enables researchers to investigate diseases that attack the blood vessels and evaluate new treatments. Researchers at the University of Zurich (UZH), the National Centre of Competence in Research Kidney.CH and the Biomaterials Science Center of the University of Basel have now developed a novel X-ray contrast agent called “XlinCA”, with which capillaries can be made visible much more precisely using computer tomography.
Previous methods often faulty
Previously, contrast agents were added to polymerizing plastic resins before they were injected into the blood vessels of euthanized animals. However, it is very difficult to completely fill out the delicate capillaries in various organs with viscous resins. “Without years of experience using the right injection techniques, the capillaries are often only partially filled, or missing entirely. Up to a quarter of the resulting images are therefore unusable,” says Willy Kuo, a postdoctoral researcher at the Institute of Physiology of UZH. By using “XlinCA” instead of other contrast agents, up to 25 percent fewer animals would be needed for experiments, states Kuo.
The basic problem with conventional methods is that plastic and water do not mix. This results in water inclusions where the contrast agent is absent, which causes disconnected vessel segments on the X-ray image. While the water-soluble X-ray contrast agents used in medicine may not have this problem, they cannot be solidified and leak through blood vessel walls into the surrounding tissue within minutes.
Optimum results thanks to custom contrast agent
Contrast agents for medical use in humans consist of small molecules and are relatively simple to produce. “A custom contrast agent for ex vivo use was significantly more difficult to synthesize, since it is made up of polymers – molecules bonded together in long chains,” says Bernhard Spingler, professor at UZH’s Department of Chemistry. “XlinCA” has several advantages over previously used X-ray contrast agents: It is easy to use and enables complete and uninterrupted vascular imaging. It also allows multiple organs or even whole animals such as mice to be examined at the same time.
Ngoc An Le, Willy Kuo, Bert Müller, Vartan Kurtcuoglu, Bernhard Spingler. Crosslinkable polymeric contrast agent for high-resolution X-ray imaging of the vascular system. Chemical Communications. 27 April 2020. DOI: 10.1039/C9CC09883F
- E.rupt selected in Future of Health Grant program
- Prometheus AG wins Orbital Reef Starter Innovation Challenge
- Prometheus and askEarth join ESA BIC Switzerland
- EraCal Therapeutics collaborates with Nestlé Health Science
- SingMax is the winner of the Bootcamp 2022
- aiEndoscopic wins Swiss Innovation Challenge
- PayMate is the winner team of the UZH Innovathon
- Arcton pitch at Start-up Nights
- Navignostics raises CHF 7.5M in seed financing round
- MUVON Therapeutics: Phase II clinical trial started
- We are hiring: Innovation Coordinator 50%
- Clemedi releases Tuberculini
- UZH spin-off Recolony idolized in 20 minutes
- InCephalo AG receives EIT Health Gold Track grant
- Entrepreneurial researchers at the Credit Suisse Entrepreneurs' Conference
- Partnering to foster the entrepreneurial journey
- Breaking communication barriers for better social inclusion
- Approval for new alzheimer’s drug developed at UZH
- Driving innovation for impact together!
- Molecular Partners teams up with Novartis to develop COVID-19 therapies
- Biotech spin-offs University of Zurich
- Join the U21 RISE Competition - Submit your environmental and/or societal development project until 18th November 2020!
- Shape the future of digital transformation - Apply for the Digital Entrepreneurship Bootcamp until 9 October 2020!
- Futurepreneuship's "Young professional program": Apply until 30 September 2020
- Italian Bilateral Scientific Cooperation Award: Apply until 31 August 2020
- EraCal nominated for The Spinoff Prize
- Pitch prize for intubation aid - Entrepreneur Fellow Dave Gage in interview
- Venture Leaders Life Sciences program
- Entrepreneur in the incubator
- Future.preneurship - Internships to explore Innovation: Apply until April 24!
- Refining Breast Cancer Classification by Multiplexed Imaging
- $60 Million for Swiss Startups - Successful Founders to Launch Venture Fund
- Milk from Teeth: Dental Stem Cells Can Generate Milk-Producing Cells
- Antibiotics with Novel Mechanism of Action Discovered
- UZH Spin-off OxyPrem put their innovative oxygen sensors in use in neonatal clinics around the world
- How Digitalization Changes Medicine
- The World of Future.preneurship
- Economic Region of Zurich is European Champion in Innovation
- EraCal Therapeutics and Legartis in Top 30 >>venture>> Finalists
- Switzerland tops European Biotech Start-Up Ranking
- HOOKIPA Pharma Announces Pricing of Initial Public Offering
- Student entrepreneurship at research-intensive universities. From a peripheral activity towards a new mainstream
- Yannick Devaud won 10'000 CHF from Venture Kick
- UZH spin-off Anaveon successfully closed a CHF 35 million Series A financing
- Future.preneurship: Application is now open for students
- UZH Innovation Hub is live!
- Winner Social Entrepreneurship Seminar 2018